ArticleInternational journal of ophthalmology2025
Intravitreal low-dose triamcinolone acetonide for nonarteritic anterior ischemic optic neuropathy.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of intravitreal low-dose (1 mg) triamcinolone acetonide (TA) in Chinese acute nonarteritic anterior ischemic optic neuropathy (NAION) patients.
methodsTwenty-eight eyes of 28 patients with acute NAION (<30d of visual acuity loss) were enrolled and given intravitreal TA (IVTA) once. Visual field (VF), best corrected visual acuity (BCVA), retinal nerve fiber layer (RNFL) thickness, ganglion cell complex (GCC) thickness, radial peripapillary capillary (RPC) density, and intraocular pressure (IOP) were evaluated at baseline and 7d, 1, 3, and 6mo after IVTA.
resultsVF and BCVA were significant improved during the follow-up according to the mean deviation (MD), visual field index (VFI), and Early Treatment Diabetic Retinopathy Study (ETDRS) scores (all
conclusionLow-dose IVTA may be an alternative safe treatment option for some NAION patients in the acute stage. However, optic nerve atrophy still existed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.